Body Composition Analysis of 10 Years versus 5 Years of Adjuvant Endocrine Therapy in Patients with Nonmetastatic Breast Cancer

Table 1

Patients baseline characteristics.

	Patients with 5 years of adjuvant endocrine therapy (n = 45)	Patients with 10 years of adjuvant endocrine therapy (n = 45)	value
Age (median)	62.5	62.8	0.521
Weight (kg)	72.2	72.6	0.529
BMI (kg/m^2)	26.1	26.3	0.809
Muscle mass index (cm/m^2)	61.5	64.1	0.217
Visceral adipose index (cm/m^2)	25.1	26.9	0.176
Tumor size
T1	37	32
T2	8	13
Lymphatic invasion
N0	35	33
N1	10	12
Number of metastatic lymph nodes
M0	45	45
ER/PE status
ER+/PR+	30	27
ER+/PR−	9	6
ER−/PR+	6	7
ER−/PR−	0	5
Her-2 status
Positive	15	23
Negative	30	22
Adjuvant endocrine therapy
Anastrozole	8	7
Letrozole	13	16
Tamoxifen	12	10
Exemestane	12	12
Previous chemotherapy
Doxorubicin + cyclophosphamide	19	18
Docetaxel + cyclophosphamide	19	22
Docetaxel + carboplatin	7	5
Target therapy (transtuzumab)
Yes	15	21
No	30	24
Surgery
Modified radical mastectomy	11	13
Breast conservation	34	32

BMI: body mass index; ER: estrogen receptor; PR: progesterone receptor; Her-2: human epidermal growth factor receptor 2.